# EDGAR Filing Document

**Accession Number:** 0001134655
**File Stem:** 0001231919-25-000533
**Filing Date:** 2025-11
**Character Count:** 19636
**Document Hash:** e87a0a4d69a14e3bcbbaeb628d58bacc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001231919-25-000533.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001231919-25-000533

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251118

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GADICKE ANSBERT
- **CENTRAL INDEX KEY:** 0001134655

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504124

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM ASSET MANAGEMENT LLC
- **CENTRAL INDEX KEY:** 0001263048

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504118

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM BioImpact LLC
- **CENTRAL INDEX KEY:** 0001687078

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504120

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER NAME:**
- **FORMER CONFORMED NAME:** BioImpact Capital LLC
- **DATE OF NAME CHANGE:** 20210831

**FORMER NAME:**
- **FORMER CONFORMED NAME:** MPM Oncology Impact Management LP
- **DATE OF NAME CHANGE:** 20161007
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM Oncology Innovations Fund GP LLC
- **CENTRAL INDEX KEY:** 0001857903

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504119

**BUSINESS ADDRESS:**
- **STREET 1:** C/O MPM BIOIMPACT
- **STREET 2:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-425-9200

**MAIL ADDRESS:**
- **STREET 1:** C/O MPM BIOIMPACT
- **STREET 2:** 399 BOYLSTON STREET, SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** MPM ONCOLOGY INNOVATIONS FUND LP
- **CENTRAL INDEX KEY:** 0001719960

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504123

**BUSINESS ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-425-9200

**MAIL ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER NAME:**
- **FORMER CONFORMED NAME:** MPM ONCOLOGY INNOVATIONS FUND L.P.
- **DATE OF NAME CHANGE:** 20171017
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Oncology Impact Fund (Cayman) Management L.P.
- **CENTRAL INDEX KEY:** 0001721036

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504121

**BUSINESS ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 6174259200

**MAIL ADDRESS:**
- **STREET 1:** 450 KENDALL STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** UBS Oncology Impact Fund L.P.
- **CENTRAL INDEX KEY:** 0001691428

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40366
- **FILM NUMBER:** 251504122

**BUSINESS ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-425-9200

**MAIL ADDRESS:**
- **STREET 1:** 399 BOYLSTON STREET
- **STREET 2:** SUITE 1100
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Werewolf Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001785530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823523180
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 200 TALCOTT AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-952-0555

**MAIL ADDRESS:**
- **STREET 1:** 200 TALCOTT AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GADICKE ANSBERT<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM ONCOLOGY INNOVATIONS FUND LP<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>UBS Oncology Impact Fund L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Oncology Impact Fund (Cayman) Management L.P.<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM BioImpact LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM Oncology Innovations Fund GP LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>MPM ASSET MANAGEMENT LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O MPM BIOIMPACT LLC<br>399 BOYLSTON STREET, SUITE 1100<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Werewolf Therapeutics, Inc. [ HOWL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-18 |  | S<sup>(1)</sup> |  | 52627<sup>(2)</sup> | D | 0.93<sup>(3)</sup> | 5428912 | I | See Footnotes<sup>(4)(5)</sup> |
| Common Stock | 2025-11-19 |  | S<sup>(1)</sup> |  | 66324<sup>(6)</sup> | D | 0.94<sup>(7)</sup> | 5362588 | I | See Footnotes<sup>(4)(8)</sup> |
| Common Stock | 2025-11-20 |  | S<sup>(1)</sup> |  | 41152<sup>(9)</sup> | D | 0.89<sup>(10)</sup> | 5321436 | I | See Footnotes<sup>(4)(11)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.

(2) The shares were sold as follows: 3,613 by MPM Asset Management LLC ("AM LLC"), 22,827 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,523 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 786 by MPM Asset Management Investors BV2014 LLC ("AM
BV2014"), 5,027 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 18,851 by UBS Oncology Impact Fund L.P. ("UBS Oncology").

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8902 to $0.9601 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is thegeneral partner of MPM OIF. MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC, a managerof MPM OIF GP and the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

(5) The shares are held as follows: 372,858 by AM LLC, 2,354,688 by BV 2014, 157,054 by BV 2014(B), 81,046 by AM BV2014, 516,458 by MPM OIF and 1,946,808 by UBS Oncology.

(6) The shares were sold as follows: 4,554 by AM LLC, 28,768 by BV 2014, 1,919 by BV 2014(B), 990 by AM BV2014, 6,335 by MPM OIF and 23,758 by UBS Oncology.

(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.901 to $0.9806 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(8) The shares are held as follows: 368,304 by AM LLC, 2,325,920 by BV 2014, 155,135 by BV 2014(B), 80,056 by AM BV2014, 510,123 by MPM OIF and 1,923,050 by UBS Oncology.

(9) The shares were sold as follows: 2,825 by AM LLC, 17,850 by BV 2014, 1,191 by BV 2014(B), 614 by AM BV2014, 3,931 by MPM OIF and 14,741 by UBS Oncology.

(10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8506 to $0.9556 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff ofthe Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(11) The shares are held as follows: 365,479 by AM LLC, 2,308,070 by BV 2014, 153,944 by BV 2014(B), 79,442 by AM BV2014, 506,192 by MPM OIF and 1,908,309 by UBS Oncology.

**Remarks:**
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2014, L.P.

**Signature:** /s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC, the GP of MPM Oncology Innovations Fund, L.P.  
**Date:** 2025-11-20

**Signature:** /s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC  
**Date:** 2025-11-20

**Signature:** /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC  
**Date:** 2025-11-20

**Signature:** /s/ Ansbert Gadicke, member of MPM Asset Management LLC  
**Date:** 2025-11-20

**Signature:** /s/ Ansbert Gadicke  
**Date:** 2025-11-20

**Signature:** /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund, L.P.  
**Date:** 2025-11-20

**Signature:** /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P.  
**Date:** 2025-11-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**